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Background: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is
an alternative treatment for seasonal allergic rhinitis with or without asthma. The
aim of this study was to assess the clinical efficacy and safety of a cumulative dose
of 170 lg LPP administered subcutaneously over 3 weeks.
Methods: In a randomized, double-blind, placebo-controlled trial, 554 adults with
grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous
injections of placebo or 170 lg LPP administered in increasing doses in 4 visits over
3 weeks. The primary outcome was the combined symptom and medication score
(CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation
test (CPT) and quality of life (QOL) was assessed as secondary endpoints.
Results: The mean reduction in CSMS in the LPP vs placebo group was 15.5%
(P = .041) during the peak period and 17.9% (P = .029) over the entire pollen season.
LPP-treated group had a reduced reactivity to CPT (P < .001) and, during the pollen sea-
son, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo
group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed
≤30 minutes in 10.5% of LPP-treated patients, whereas 3 patients with a medical his-
tory of asthma (<1%) experienced a serious ESR that resolved with rescue medication.
Conclusion: Lolium perenne pollen peptides administered over 3 weeks before the grass
pollen season significantly reduced seasonal symptoms and was generally safe and well-
tolerated.
Abbreviations: (E)SR, (early) systemic reaction; AIT, allergen immunotherapy; CPT, conjunctival provocation test; CSMS, combined clinical symptom/medication score; EAACI, European
Academy of Allergy and Clinical Immunology; ESS, Eye symptoms score; LPP, Lolium perenne pollen peptides; NSS, nose symptom score; QOL, quality of life; RMS, rescue medication score;
RTSS, rhinoconjunctivitis total symptom score; SCIT, subcutaneous immunotherapy; WAO, World Allergy Organization.
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1 | INTRODUCTION
Allergic rhinitis with and without asthma affects at least 400 million
people worldwide, and the current estimated prevalence is up to 40%.
Pharmacotherapy with antihistamines and nasal corticosteroids can
provide symptomatic relief in most but not all patients.1,2 Allergen
immunotherapy (AIT), administered either subcutaneously or sublingually,
provides long-term relief of allergy symptoms and is recommended for
patients whose seasonal allergies are not effectively controlled by
pharmacotherapy.3-6 However, patient adherence to AIT is low, and
therefore, efficiency is suboptimal because current immunotherapy
regime requires frequent treatment over several years.7-9
Adjuvant-free allergen peptide hydrolysates ranging 1-10 kDa
from Lolium perenne (LPP) for immunotherapy use have been shown to
have limited IgE binding, basophil, and mast cell reactivity and hence
are considered as a safe alternative that can be administered at higher
doses and for a shorter period to improve treatment adherence.10,11
Moreover, in a dose-response, double-blind, placebo-controlled study
where 198 adults with grass pollen-induced allergic rhinitis received
either placebo, 70, 170, or 370 lg, a cumulative dose of 170 lg of
LPP over 3 weeks was the optimal dose in terms of surrogate efficacy
and benefit/risk balance.12 In this study, a dose-dependent allergen-
specific IgG4 and blocking antibodies were induced.
We sought to investigate the clinical efficacy and safety of a
cumulative dose of 170 lg LPP administered subcutaneously over
3 weeks. Here, we present the results of a multicenter, randomized,
double-blind, placebo-controlled trial with grass pollen-allergic
patients treated in 4 visits over 3 consecutive weeks with LPP. Clini-
cal efficacy was primarily assessed using the combined clinical symp-
tom and medication score (CSMS) as recommended by the European
Academy of Allergy and Clinical Immunology (EAACI).13 In addition,
patient QOL reactivity and CPT reactivity to grass pollen allergen
were assessed, and adverse events were documented.
2 | METHODS
2.1 | Study design and ethics
This was a randomized, double-blind, placebo-controlled, interna-
tional and multicenter trial conducted in 57 sites in six countries in
Europe (Belgium, Czech Republic, Germany, France, Italy, and Spain)
between January and September, 2016 (ClinicTrials.gov no.
NCT02560948; EudraCT no. 2015-002105-11). The primary objec-
tive was to demonstrate the clinical efficacy of a cumulative dose of
170 lg LPP over the peak pollen season as measured using the
CSMS. The study was reviewed and approved by local regulatory
authorities and independent ethics committees in each country and
was conducted in accordance with the Declaration of Helsinki in its
revised edition (64th World Association General Assembly, Fortaleza,
Brazil, October 2013) and International Conference on Harmoniza-
tion Good Clinical Practice. All patients provided written informed
consent.
2.2 | Patients
Between January 14, 2016 and March 26, 2016, 554 adults were
included according to inclusion criteria below and randomized (182
to placebo and 372 to LPP). Follow-up of the last patient was com-
pleted on September 15, 2016. Nine patients withdrew before the
treatment phase and did not receive study product, 28 withdrew
during the treatment phase, and 5 withdrew after the treatment
phase, so that among those who completed the study, ITT efficacy
analysis included 171 patients in the placebo group and 339 patients
in the LPP group (Figure 1). Adults aged 18-64 years and allergic to
grass pollen were enrolled if they had a medical history of moder-
ate-to-severe seasonal allergic rhinoconjunctivitis during at least the
two previous seasons as defined by the Allergic Rhinitis and its
Impact on Asthma guidelines.14 Patients also had a positive skin
prick test (wheal diameter ≥ 3 mm, mean of orthogonal diameters)
to grass pollen mix extract, specific IgE against grass pollen aller-
gens > 0.7 kU/L, a positive CPT to grass pollen allergen (≤10 000
standardized quality units; see Data S1) and have received anti-aller-
gic medications for at least two consecutive grass pollen seasons.
Patients with confirmed diagnosis of grass pollen-induced controlled
asthma according to the 2014 Global Initiative for Asthma guidelines
were included in the study as well.15
Patients were excluded if they had received immunotherapy with
grass pollen allergens within the preceding 5 years, were currently
receiving immunotherapy of any kind, had a history of anaphylaxis,
were hypersensitive to the excipients of the investigational product,
had a forced expiratory volume in 1 second <80% of the predicted
value or a peak expiratory flow <70%, were symptomatic to other
inhaled allergens present during the grass pollen season or to peren-
nial inhaled allergens (house dust mites, cat, dog) to which they
were regularly exposed, or had a contraindication for epinephrine.
Patients with a history of significant renal disease, chronic hepatic
disease, malignant disease, and severe autoimmune disease were
excluded.
2.3 | LPP and placebo
Lolium perenne pollen peptides is an adjuvant-free mixture of pep-
tides (1-10 kDa) resulting from the enzymatic hydrolysis of
L. perenne purified proteins as described in Shamji et al.11 LPP was
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supplied in ready-to-use vials containing 1.5 mL of 100 lg/mL grass
pollen peptides in sterile aqueous-buffered solution (pH 7.4). The
placebo was provided in identical ready-to-use vials containing
1.5 mL of sterile aqueous-buffered solution. The vials were num-
bered with computer-generated randomization codes.
2.4 | Study design
Eligible patients were randomized 2:1 to LPP or placebo. Treatments
were assigned using a central allocation system. Each treatment con-
sisted of eight subcutaneous injections at 4 visits over 3 consecutive
weeks between January and April, 2016. At each treatment visit, the
patient received a first injection in one arm, followed 30 minutes
later by a second injection in the opposite arm. Doses were
increased incrementally starting with 2 9 5 lg at 1st visit,
2 9 10 lg at 2nd visit, 2 9 20 lg at 3rd visit and 2 9 50 lg of LPP
at the last treatment visit, (Figure S1). The resulting cumulative dose
was 170 lg of LPP. After the two injections, patients remained
under physician supervision for another 30 minutes. Local reactions
and SRs occurring within 48 hours following each injection were
reported. SRs were graded according to the World Allergy Organiza-
tion (WAO) scale from 1 to 4.16 Patients were discontinued if they
had a serious SR (grade 3 or 4) at any visit or had a local wheal reac-
tion >8 cm in diameter within 30 minutes after injection or a con-
firmed grade 2 SR during the first treatment visit. In case of a local
wheal of 5-8 cm in diameter (within 30 minutes) or a grade 1 SR,
the same dose was to be repeated at the next treatment visit.
Patients who had a local wheal >8 cm (within 30 minutes) or a grade
2 SR during one of the last three treatment visits were de-escalated
to the dose injected at the previous visit for the next visit. In case, a
dose adjustment was necessary, up to two additional treatment visits
were allowed to reach the cumulative dose of 170 lg. All patients
were provided with fexofenadine (180 mg) as rescue medication to
relieve any local reaction. Follow-up visits occurred before (March/
April), during (June), and after the grass pollen season (August). Dur-
ing the pollen season, all patients were provided with desloratadine
5-mg tablets, levocabastine 0.5 mg/mL eye drops, and fluticasone
propionate 50 lg/dose nasal spray. Upon request, patients were
provided with methylprednisolone 16-mg tablets. Asthmatic patients
were also provided with budesonide 160 lg/formoterol fumarate
dihydrate 4.5 lg.
2.5 | Endpoints
The primary endpoint was the daily CSMS during the peak pollen
period, which was calculated as the daily rhinoconjunctivitis total
symptom score (RTSS)/6+ rescue medication score (RMS) over the
peak of the grass pollen season, as described previously.13 Second-
ary efficacy endpoints included individual symptom (NSS, ESS) and
medication scores over the peak and entire pollen season, and num-
ber of well days. A well day was defined as a day with a RTSS ≤ 2
and no rescue medication needed (RMS = 0). Change in CPT
F IGURE 1 Patient disposition. A total
of 554 patients were included and
randomized. Of the 182 patients
randomized to placebo, 178 started
treatment, of which 3 discontinued
treatment early, 2 discontinued before the
end of the study, and 173 completed the
trial. Of the 372 patients randomized to
LPP, 367 started treatment, of which 22
discontinued treatment early, 6
discontinued before the end of the study,
and 339 completed the trial. ITT
population consisted of 171 placebos and
339 LPP-treated patients. AE, adverse
event; LPP, Lolium perenne pollen peptides
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reactivity was assessed before and after treatment and was scored
from 0 (unreactive) to 4 (highest) as described previously17,18 (see
Data S1 for details). Quality of life was evaluated using the
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)19 and Noc-
turnal Rhinoconjunctivitis Quality of life questionnaire (NRQLQ)20 at
a visit prior to the pollen season (V6) and at a visit during the pollen
season (V7). Safety endpoints included local reactions and SRs
graded according to the WAO scale,16 and unsolicited treatment-
emergent adverse events (TEAEs) and serious adverse events coded
using MedDRA version 19.0 (MedDRA MSSO, McLean, VA, USA).
2.6 | Definition of pollen season and the pollen
peak
Start and end dates of the grass pollen season and of the grass pol-
len peak period were determined for each region or country based
on official pollen count data. The pollen season start was defined as
the first of 5 consecutive days with a pollen count ≥10 grains/m3 of
air and the last day of the pollen season as the first of 5 consecutive
days with a pollen count <10 grains/m3 of air. The grass pollen peak
period was defined as the 14-day period with the highest pollen
counts.
2.7 | Study size estimate
Using a 2:1 randomization ratio and assuming a mean daily CSMS of
1.55 in the placebo group with a standard deviation of 1.0, a sample
size of 165 patients in the placebo group and 330 patients in the
LPP group is needed to detect a statistically significant (P < .05) dif-
ference in mean daily CSMS of 20% between the 2 groups with a
power of 90%.13 To account for a 10% and a 15% dropout rate dur-
ing the treatment phase and the pollen season, respectively, 654
randomized patients were targeted for corticosteroids.
2.8 | Statistical analysis
Statistical analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC, USA). The primary analysis was the intention-to-
treat (ITT) using the efficacy assessments from all patients who
TABLE 1 Efficacy assessments
Periods Measures Treatments N Mean  SD Absolute differences Relative differences (%) P-values
Pollen peak CSMS (primary endpoint) Placebo 136 1.475  1.049 0.228 15.5 .041
LPP 264 1.247  0.972
RTSS Placebo 150 4.498  3.513 0.833 18.5 .013
LPP 284 3.665  3.169
RMS Placebo 108 0.698  0.620 0.104 14.9 .152
LPP 222 0.594  0.595
Nose symptom score Placebo 156 3.318  2.502 0.614 18.5 .007
LPP 289 2.704  2.335
Eye symptom score Placebo 150 1.222  1.215 0.248 20.3 .046
LPP 287 0.974  1.093
Well days Placebo 102 33.193  37.063 7.638 23.0 .044
LPP 208 40.831  36.131
Entire season CSMS Placebo 95 1.189  0.856 0.213 17.9 .029
LPP 201 0.976  0.810
RTSS Placebo 86 3.168  2.423 0.495 15.6 .073
LPP 186 2.673  2.171
RMS Placebo 64 0.577  0.577 0.125 21.7 .127
LPP 144 0.452  0.486
Nose symptom score Placebo 98 2.340  1.661 0.285 12.2 .097
LPP 196 2.055  1.656
Eye symptom score Placebo 94 0.892  0.947 0.194 21.8 .115
LPP 202 0.698  0.751
Well days Placebo 46 42.188  34.968 10.530 24.9 .082
LPP 113 52.718  33.019
Values are shown according to the treatment planned. P-values were calculated by Wilcoxon rank sum test.
CSMS, combined symptom and medication score; LPP, Lolium perenne peptides; RMS, rescue medication score; RTSS, rhinoconjunctivitis total symptom
score; SD, standard deviation.
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received at least one dose of study treatment and had at least one
record of the primary efficacy measure on at least 1 day during the
observation period. The primary efficacy assessment was the reduc-
tion in CSMS over the peak pollen season for LPP vs placebo, with
missing data replaced as recommended by the Committee for Medic-
inal Products for Human Use Guideline on Missing Data in Confir-
matory Clinical Trials (see Data S1).21 Baseline demographics and
allergy characteristics were analyzed in all randomized patients.
CSMS, its related subscores, well days, and QOL scores were com-
pared by Wilcoxon rank sum test as they were not normally dis-
tributed. Improvement in CPT reactivity was compared by Cochran-
Mantel Haenszel chi-squared test, and change in CPT score from
baseline was compared by Mann-Whitney test. A P-value below .05
was considered to indicate statistical significance.
3 | RESULTS
Five hundred and fifty-four patients were randomized and 512
(92%) completed treatment (Figure 1). Demographics and baseline
disease characteristics were similar between the placebo and LPP
groups (Table S1). The most common cosensitization in both groups
was birch pollen, followed by house dust mites, cat epithelia, and
dog epithelia. Approximately one-quarter (24.1%) of patients were
asthmatic. The full cumulative dose was reached by 329 patients
(89.4%) in the LPP and 171 patients (96.6%) in the placebo group.
Most of these received the full treatment in the planned eight injec-
tions (312/329 [94.8%] for LPP and 168/171 [98.3%] for placebo).
Seventeen (5.2%) patients in the LPP group and three (1.7%) in the
placebo group reached the full treatment in more than eight injec-
tions. Eight additional patients in the LPP group (0.6%) received the
maximum of 12 injections but did not reach the targeted cumulative
dose of 170 lg. The remaining patients discontinued for various rea-
sons, as detailed in Figure 1.
3.1 | Clinical efficacy outcomes
The mean daily CSMS during the peak pollen period was significantly
lower in the LPP group than in the placebo group (the primary effi-
cacy assessment), indicating better control of symptoms in the LPP
group than in the placebo group (Table 1). The treatment effect cor-
responded to a relative mean difference of 15.5% in favor of LPP
(P = .041). Similarly, mean daily RTSS, NSS, ESS were also signifi-
cantly lower in the LPP group compared with placebo (Table 1), but
not for RMS. Patients in the LPP group had more number of well
days (+23.0%, P = .044) during the peak pollen period than patients
in the placebo group.
When assessed over the entire pollen season, the difference in
CSMS was 17.9% in favor of LPP (P = .029; Figure S1, Table 1).
F IGURE 2 Conjunctival provocation test (CPT) reactivity. A CPT
with grass pollen extract was performed at baseline and after
completion of treatment (visit 6). Shown are the proportions of
patients receiving placebo (n = 56/149) and LPP (n = 177/295) with
a decrease in CPT score from baseline, and those without. Results
are for the ITT population. Proportions were compared by chi-
squared test. LPP, Lolium perenne pollen peptides
F IGURE 3 Impact of baseline conjunctival provocation test (CPT)
reactivity on CSMSs. Comparison of the mean daily combined
symptom and medication score (CSMS) during the peak pollen
period (A) and during the entire pollen season (B) in the placebo and
Lolium perenne pollen peptides (LPP) groups for the whole
population and for the subpopulation of patients with a CPT score
of 3 and 4 at baseline. Data are presented as mean  SEM
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Similarly, RTSS, RMS, ESS, NSS, and number of well days were all
better in the LPP group, although differences were not significant.
Reactivity to CPT before and after treatment was assessed as a
secondary endpoint, as surrogate of the clinical effect anticipated.
CPT reactivity decreased in significantly more patients in the LPP
group (177/295 [60.0%]) than in the placebo group (56/149 [37.6%])
(P < .0001) (Figure 2). The mean change in CPT score was also sig-
nificantly larger in the LPP group than in the placebo group
(0.8  0.8 vs 0.4  0.9, P < .001; Table S2). In a post hoc analy-
sis, the relationship between CPT reactivity at baseline and the
CSMS during the peak pollen period and entire pollen season was
assessed. Both the mean CSMS in the placebo group and the differ-
ence in mean CSMS between the placebo and LPP group, increased
when the CPT reactivity at baseline was higher (Table S3). When
looking at the most CPT reactive patients, that is, those with a base-
line CPT score of 3 or 4 (representing 57.9% the patients, Table S3),
the mean relative difference of CSMS was 19.8% (P = .051) over
the peak period and 24.4% (P = .047) over the entire pollen season
(Figure 3A-B and Table S4).
3.2 | Quality of life assessments
Whereas overall RQLQ and NRQLQ scores were similar in both
groups prior to the pollen season, patients in the LPP group reported
a better rhinoconjunctivitis-related QOL during the pollen season
than those in the placebo group (Table 2). A significant treatment
effect was observed at V7 (17.1%; P = .005) with the overall
RQLQ assessment. Similarly, overall NRQLQ score was significantly
lower in the LPP group at the visit performed during the grass pollen
season. Also in most RQLQ and NRQLQ subdomains, mean scores
were significantly lower in the LPP group compared with placebo. In
a post hoc analysis, the treatment effect on QOL in patients with
highest CPT reactivity at baseline was found to reach 29.2% for
RQLQ and 20.7% for NRQLQ (Table S5).
3.3 | Safety outcomes
Early systemic reactions (ESR, ie, within 30 minutes of treatment)
were reported in 10.1% of patients (37/368) in the LPP group and
TABLE 2 Quality of Life assessments during the pollen season
Measures Treatments N Mean  SD Relative differences (%) P-values
Overall RQLQ Scores Placebo 170 1.407  1.104 17.1 .005
LPP 332 1.167  1.063
Activity limitations Placebo 170 1.831  1.451 12.3 .093
LPP 336 1.606  1.381
Sleep problems Placebo 170 0.914  1.260 23.1 .066
LPP 336 0.702  1.096
Non-nose/eye symptoms Placebo 170 1.240  1.259 20.9 .011
LPP 335 0.981  1.188
Practical problem Placebo 170 2.220  1.594 13.8 .025
LPP 335 1.914  1.557
Nose symptoms Placebo 170 1.875  1.342 15.3 .015
LPP 335 1.588  1.276
Eye symptoms Placebo 170 1.224  1.220 12.0 .122
LPP 332 1.076  1.166
Emotional function Placebo 170 0.860  1.133 21.2 .018
LPP 333 0.687  1.086
Overall NRQLQ Scores Placebo 170 0.944  0.907 16.5 .006
LPP 338 0.789  0.910
Sleep problems Placebo 171 0.754  1.077 24.3 .014
LPP 338 0.571  0.961
Sleep time problems Placebo 170 0.774  0.927 17.3 .028
LPP 339 0.640  0.888
Symptoms on waking in the morning Placebo 171 1.069  1.123 17.2 .009
LPP 338 0.885  1.121
Practical problems Placebo 171 1.310  1.004 8.0 .025
LPP 339 1.205  1.246
Values are shown according to the treatment planned based on observed cases. P-values were calculated by Wilcoxon rank sum test.
LPP, Lolium perenne peptides, SD, standard deviation.
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in 2.3% (4/177) in the placebo group (Table 3). All but two were
WAO grade 1 or 2. Three ESRs were reported as serious in 3
patients with a history of asthma belonging to the LPP group: one
grade 2, one grade 3, and one grade 4 ESR (WAO). These were
resolved with rescue medication but resulted in withdrawal from
the trial. Only the grade 4 ESR required the administration of epi-
nephrine. Seventeen participants who had dose adjustments due to
ESRs eventually reached the full target dose. Systemic reactions
occurring later than 30 minutes were less severe (Table 3), and
none was serious: Only 4 (1.1%) patients experienced a WAO
grade 2 reaction (compared to 3.5% within 30 minutes), and no
grade 3 and 4 WAO systemic reaction occurred. Local reactions at
the injection site were reported for 28.5% (105 of 368) of patients
in the LPP group and 2.8% (5 of 177) in the placebo group. Most
were mild (99 for LPP, 7 for placebo). The remainder were moder-
ate (12 for LPP, 1 for placebo). In all cases, the event resolved
without medical assistance, and none was considered as serious.
No wheal diameter exceeded 5 cm, 30 minutes after injection, and
so no dose adjustment was required per protocol. Nineteen
patients (5.2%) discontinued the study treatment due to a TEAE
considered as related to LPP (some of which continued in the
study), the main cause being a SR.
4 | DISCUSSION
For the first time, we report the clinical efficacy and safety of a 3-week
treatment administered subcutaneously over 4 visits prior the grass
pollen season with an adjuvant-free Lollium perenne peptides (LPP)
ranging 1-10 kDa. CSMS was reduced in LPP-treated group compared
with placebo. Furthermore, LPP treatment was well tolerated as the
majority of the patients reached accumulative dose of 170 lg.
The primary outcome measure was the assessment of the daily
CSMS during the peak pollen season. In this study, we showed a sig-
nificantly lower mean CSMS over the peak pollen season of 15% for
LPP vs placebo. The low magnitude in the reduction may have been
due to a relatively mild grass pollen allergy season, as indicated by
relatively low symptom scores (mean RTSS <4.5 out of a maximum
of 18 during peak and <3.2 over the entire season) and low rescue
medication use in the placebo arm: The mean RMS in the placebo
group during both the pollen peak (0.698) and the full pollen season
(0.577) indicated that, on average, only 2 of 3 patients used any res-
cue medications daily. It is well known that the magnitude of effi-
cacy measurements in grass allergy immunotherapy trials is highly
dependent on the natural pollen exposure.22,23 Consistent with these
findings, post hoc analysis showed that the difference in CSMS dur-
ing the pollen peak was about 20% when limited to patients with
more severe grass pollen sensitivity at baseline (representing 57.9%
of the whole study population) and 24.4% over the entire pollen sea-
son.
Short-course immunotherapy approach with whole allergen
extract has been used in grass pollen-induced allergic rhinitis. One
study showed a 26.6% decrease in median combined score during
the first year and a 48.4% decrease the second year in grass pollen-
allergic adults who received weekly subcutaneous of alum-adsorbed
six-grass pollen extract just before each pollen season.24 A decrease
of 12.7% during the entire grass pollen season and 13.6% during the
pollen peak was reported in patients who received four preseason
subcutaneous injections of monophosphoryl lipid A-adjuvanted tyro-
sine-adsorbed 13-grass pollen extract.25 A decrease of 15.6% the
first year and 33% the second year was reported in patients who
each year received five preseason subcutaneous injections of alum-
adsorbed depigmented grass pollen extract.26 Although comparison
of results of different studies has to be performed with caution
because scores, statistical methods, study designs, pollen seasons,
and regions may be different, the 15.5%-24.4% improvement in
CSMS observed after LPP treatment appeared to be within the
range reported for other short-term grass pollen immunotherapies
with adjuvanted products.
The effect of LPP appeared to be more pronounced on the
changes in allergic symptoms (mean RTSS, NSS, and ESS were signif-
icantly lower with LPP than with placebo), than on rescue medica-
tion. In agreement with this, patients receiving LPP also had more
well days, a lower impairment of quality of life in season (diurnal and
nocturnal) and a greater decrease in grass pollen CPT scores than
patients receiving placebo.
Injections with whole pollen antigens can cause severe systemic
reactions, so injections must be performed under medical supervision
where resuscitation equipment is available, and patients need to be
monitored for 30-60 minutes after injections.27 At the same doses,
LPP are less likely than the whole grass pollen allergen protein to
cross-link high-affinity IgE receptors and cause allergic reactions,
TABLE 3 Solicited systemic reactions
WAO grade
Placebo LPP
N = 177 N = 368
Events Patient, n (%) Events Patient, n (%)
Occurrence within 30 min of injection
Any 5 4 (2.3) 49 37 (10.1)
Grade 1 5 4 (2.3) 34 25 (6.8
Grade 2 0 0 (0.0 13a 13 (3.5)
Grade 3 0 0 (0.0) 1b 1 (0.3)
Grade 4 0 0 (0.0) 1c 1 (0.3)
Occurrence later than 30 min after injection
Any 4 4 (2.3) 48 41 (11.1)
Grade 1 3 3 (1.7) 44 37 (10.1)
Grade 2 1 1 (0.6) 4 4 (1.1)
Results are shown according to the treatment received. Reactions were
graded according to the WAO scale.14
LPP, Lolium perenne peptides; WAO, World Allergy Organization.
aIncluded one serious event of bronchospasm with dyspnea and wheez-
ing, followed by generalized urticaria.
bIncluded one serious event of conjunctival injection, throat clearing, and
urticaria, followed by abdominal cramps, retrosternal pain, dyspnea, nau-
sea, and extension of the urticaria.
cIncluded one serious event of tightness of the chest, followed by dizzi-
ness and decreased blood pressure.
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although LPP is administered at higher dose to allow for the short-
course treatment regimen.11 Three patients (<1%) treated with LPP
had grades 2-4 serious systemic hypersensitivity reactions, resulting
in discontinuation from the study. However, all occurred within
30 minutes of injection and resolved with rescue medication. In each
of the three cases, the patient had a history of asthma, a known risk
factor for early SRs to SCIT.28,29 By comparison, Frew et al30
reported that alum-adsorbed grass pollen extract (Phleum pratense)
induced ESRs in 32.5% of patients and EAACI grade 3 ESRs in 4.4%
of patients with grass pollen allergy. In this study, ESRs were
reported in 10.5% of the patients and WAO grade ≥3 ESR in 0.6%.
Although a different grading system was used than the current
study, the data of this study suggest that LPP was overall well toler-
ated, in agreement with the concept of peptide immunotherapy.10
Importantly, 89% reached the full dose of 170 lg LPP in the planned
eight injections (four treatment visits of two injections) and another
5% reached the full dose after a dose adjustment.
A limitation of this study was an unexpectedly high number of
screening failures, which was mainly due to the exclusion of patients
in whom birch pollen allergy was dominant. Despite this, the popula-
tion was large enough to detect clinically and statistically significant
improvements in allergic rhinitis symptoms as well as relevant safety
data. The modest CSMS treatment effect observed may also be due
to the inclusion of patients with limited allergy severity, as suggested
by the increased treatment effect observed in patients with highest
CPT reactivity at baseline. Another apparent limitation is the number
of missing data, especially outside the peak pollen period, which is
due to noncompliance of patients with the requirement of scoring
symptoms and medication on a daily basis for several weeks, even in
the absence of symptoms. Considering that all efficacy data show
similar results, including the QOL scores for which only a limited
number of data were available, these missing data are not consid-
ered to impact significantly on efficacy data and conclusions.
In conclusion, this study showed that a short-course treatment
with LPP over 3 weeks just before the pollen season was effective
and limited CSMS in patients with seasonal allergic rhinitis with and
without asthma. LPP offers the possibility of a much shorter treat-
ment course and therefore better compliance and efficiency than
standard SCIT using conventional whole allergen extracts. LPP treat-
ment was safe and well tolerated. However, as with conventional
SCIT, patients should be monitored for adverse reactions, and dose
adjustment should be made if necessary.
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